Supplemental Table 1
Immunophenotype at Baseline, by Study

		S0112 N=60	S0301: original eligibility criteria N=14	S0301: revised eligibility criteria N=50
CD13	Negative	1 (2%)	0	1 (2%)
	Weak Positive	13 (26%)	1 (8%)	23 (47%)
	Positive	36 (72%)	11 (92%)	25 (51%)
	Not Done	0	2	1
CD33	Negative	1 (2%)	0	1 (2%)
	Weak Positive	22 (45%)	11 (79%)	28 (61%)
	Positive	26 (53%)	3 (21%)	17 (37%)
	Not Done	1	0	4
CD34	Negative	10 (20%)	3 (21%)	23 (46%)
	Weak Positive	10 (20%)	2 (14%)	11 (22%)
	Positive	30 (60%)	9 (64%)	16 (32%)
CD45	Negative	0 (0%)	0 (0%)	0 (0%)
	Weak Positive	6 (12%)	1 (7%)	2 (4%)
	Positive	44 (88%)	13 (93%)	45 (96%)
	Not Done	0	0	3

Supplemental Table 2
Effects of Immunophenotype on Response to Induction Chemotherapy, by Study

		Study S0112			Study S0301: revised eligibility criteria		
		Patients	Complete Response	Resistant Disease	Patients	Complete Response	Resistant Disease
CD13	Negative	1	0 (0%)	1 (100%)	1	1 (100%)	0 (0%)
	Weak Positive	13	6 (46%)	2 (15%)	23	10 (43%)	5 (22%)
	Positive	36	13 (36%)	13 (36%)	25	11 (44%)	7 (28%)
	Not Done	0	---	---	1	0 (0%)	1 (100%)
	Trend [a]		P = 0.66	P = 0.32		P = 0.90	P = 0.56
CD33	Negative	1	0 (0%)	1 (100%)	1	1 (100%)	0 (0%)
	Weak Positive	22	7 (32%)	8 (36%)	28	12 (43%)	6 (21%)
	Positive	26	12 (46%)	7 (27%)	17	9 (53%)	4 (24%)
	Not Done	1	0 (0%)	0 (0%)	4	0 (0%)	3 (75%)
	Trend [a]		P = 0.26	P = 0.36		P = 0.59	P = 0.82
CD34	Negative	10	6 (60%)	3 (30%)	23	12 (52%)	6 (26%)
	Weak Positive	10	5 (50%)	5 (50%)	11	4 (36%)	2 (18%)
	Positive	30	8 (27%)	8 (27%)	16	6 (38%)	5 (31%)
	Trend [a]		P = 0.043	P = 0.32		P = 0.53	P = 0.56
CD45	Negative	0	---	---	0	---	---
	Weak Positive	6	2 (33%)	1 (17%)	2	2 (100%)	0 (0%)
	Positive	44	17 (39%)	15 (34%)	45	20 (44%)	11 (24%)
	Not Done	0	---	---	3	0 (0%)	2 (67%)
	Trend [a]		P = 0.80	P = 0.39		P = 0.12	P = 0.42

[a] Two-sided p-value based on the χ^2 approximation to the Fisher's exact test, testing positive versus negative or weak positive, and excluding patients with assay not done.

Supplemental Table 3
Effects of Demographic and Disease Characteristics at Baseline on Response to Induction Chemotherapy, by Study

		Study S0112			Study S0301: revised eligibility criteria		
		Patients	Complete Response	Resistant Disease	Patients	Complete Response	Resistant Disease
Performance Status	0	20	19 (65%)	5 (25%)	18	8 (44%)	6 (33%)
	1	25	9 (36%)	6 (24%)	28	12 (43%)	6 (21%)
	2	11	1 (9%)	6 (55%)	4	2 (50%)	1 (25%)
	3	4	0 (0%)	2 (50%)	0	---	---
	Trend [a]		P = 0.003	P = 0.43		P = 0.96	P = 0.38
AML Onset	De novo	44	22 (50%)	12 (27%)	42	19 (45%)	11 (26%)
	MDS-related	14	0 (0%)	6 (43%)	7	2 (29%)	2 (29%)
	Treatment-related	2	1 (50%)	1 (50%)	0	---	---
	Unknown	0	---	---	1	1 (100%)	0 (0%)
	Trend [b]		P = 0.002	P = 0.23		P = 0.41	P = 0.89
Cytogenetic Risk Classification	Evaluable	51	---	---	31	---	---
	Unfavorable [c]	19	7 (37%)	6 (32%)	12	5 (42%)	5 (42%)
	Intermediate [c]	29	11 (38%)	9 (31%)	16	10 (63%)	2 (13%)
	- Normal [c]	25	11 (44%)	7 (28%)	11	7 (64%)	1 (9%)
	Favorable [c]	3	3 (100%)	0 (0%)	3	1 (33%)	0 (0%)
	Trend [d]		P = 0.87	P = 0.99		P = 0.85	P = 0.16
WBC (1000/mcL)	≤ 4.0	23	10 (43%)	6 (26%)	16	7 (44%)	7 (44%)
	4.01 – 20.0	21	8 (38%)	7 (33%)	15	8 (53%)	3 (20%)
	> 20.0	16	5 (31%)	6 (38%)	19	7 (37%)	3 (16%)
	Trend [e]		P = 0.89	P = 0.42		P = 0.79	P = 0.078

[a] Two-sided p-value based on the χ^2 approximation to the Fisher's exact test, testing performance status of 0 versus >0.

[b] Two-sided p-value based on the χ^2 approximation to the Fisher's exact test, testing de novo versus MDS- or treatment-related AML, excluding unknown AML onset.

[c] Percentages based on number with evaluable cytogenetics.

[d] Two-sided p-value based on the χ^2 approximation to the Fisher's exact test, testing unfavorable versus favorable or intermediate, excluding patients without evaluable cytogenetics.

[e] Two-sided p-value based on logistic regression treating WBC as a continuous covariate.